Calls for papers
-
In December 2021, inhaled drug developer Aerami Therapeutics announced that it would go public by merging with FoxWayne Enterprises Acquisition Corp, a special purpose acquisition company (SPAC). The two companies have now announced that the deal… Read more . . .
-
According to Medical Developments International (MVP), the FDA has lifted a clinical hold on MVP’s Penthrox methoxyflurane inhaler and, as a result, MVP is now preparing a Phase 3 trial of Penthrox for trauma pain… Read more . . .
-
Sorrento Therapeutics announced that the FDA has given the company the okay to move ahead with a Phase 1 trial of its Covishield (STI-9199) intranasal antibody cocktail in healthy volunteers. According to Sorrento, in vitro… Read more . . .
-
BlueWillow Biologics and Medigen Vaccine Biologics Corporation (MVC) have announced that a preclinical study of their BW-1019 intranasal COVID-19 booster demonstrated that giving the nasal vaccine after intramuscular vaccination induced neutralizing antibodies and protected against disease in… Read more . . .
-
Non-profit pharma company Harm Reduction Therapeutics (HRT) said that a Phase 1 clinical trial of its HRT001 naloxone nasal spray in healthy volunteers met its primary endpoint, demonstrating the bioequivalence of a 3.0 mg dose… Read more . . .
-
Broughton, a CRO that offers development and analysis of inhaled drugs, especially nicotine and cannabinoid products, has announced the establishment of a US subsidiary. Tony Jones, who has most recently been Senior Managing Health Scientist… Read more . . .
-
DPI developer Pulmatrix has hired Margaret Wasilewski as its Chief Medical Officer, the company said. Wasilewski most recently offered consulting services as President of ID Remedies, and her previous experience includes clinical development positions at… Read more . . .
-
TFF Pharmaceuticals has partnered with CDMO Catalent for scale-up and manufacturing of dry powder formulations based on TFF’s thin film freezing technology the companies have announced. The partnership will make the TFF technology available to… Read more . . .
-
The Journal of Aerosol Medicine and Pulmonary Drug Delivery, the official journal of the International Society for Aerosols in Medicine (ISAM), has announced that GSK VP US Medical and Therapy Head for Respiratory Thomas G.… Read more . . .
-
The COPD Foundation has partnered with ENA Respiratory for development of ENA’s INNA-051 pegylated TLR2/6 agonist pan-antiviral nasal spray in patients with chronic lung disease, the company said. In June 2021, ENA Respiratory announced that… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland